Bridgeway Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Bridgeway Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$391K	Hold	26,700	–	–	0.01%	868
2025 Q4	$206K	Sell	26,700 -40,000	-60%	-$315K	﹤0.01%	1012
2025 Q3	$492K	Hold	66,700	–	–	0.01%	807
2025 Q2	$267K	Buy	66,700 +25,400	+62%	+$92.4K	0.01%	894
2025 Q1	$131K	Hold	41,300	–	–	﹤0.01%	994
2024 Q4	$221K	Sell	41,300 -86,000	-68%	-$642K	﹤0.01%	984
2024 Q3	$672K	Hold	127,300	–	–	0.01%	783
2024 Q2	$232K	Sell	127,300 -97,000	-43%	-$181K	0.01%	1023
2024 Q1	$399K	Buy	224,300 +75,000	+50%	+$157K	0.01%	982
2023 Q4	$263K	Hold	149,300	–	–	0.01%	1081
2023 Q3	$218K	Buy	149,300 +40,000	+37%	+$84.6K	0.01%	1083
2023 Q2	$250K	Sell	109,300 -50,000	-31%	-$104K	0.01%	1084
2023 Q1	$145K	Hold	159,300	–	–	﹤0.01%	1167
2022 Q4	$135K	Hold	159,300	–	–	﹤0.01%	1169
2022 Q3	$130K	Hold	159,300	–	–	﹤0.01%	1224
2022 Q2	$158K	Hold	159,300	–	–	﹤0.01%	1140
2022 Q1	$261K	Sell	159,300 -65,000	-29%	-$119K	0.01%	1119
2021 Q4	$541K	Buy	224,300 +65,000	+41%	+$252K	0.01%	960
2021 Q3	$771K	Sell	159,300 -50,000	-24%	-$148K	0.01%	906
2021 Q2	$559K	Buy	209,300 +5,000	+2%	+$13.8K	0.01%	1035
2021 Q1	$629K	Buy	204,300 +70,600	+53%	+$255K	0.01%	1032
2020 Q4	$476K	Hold	133,700	–	–	0.01%	965
2020 Q3	$536K	Hold	133,700	–	–	0.01%	861
2020 Q2	$364K	Hold	133,700	–	–	0.01%	967
2020 Q1	$282K	Hold	133,700	–	–	0.01%	949
2019 Q4	$727K	Buy	+133,700	New	+$468K	0.01%	826
2019 Q2	–	Sell	-89,000	Closed	-$358K	–	1336
2019 Q1	$358K	Buy	89,000 +9,400	+12%	+$39.7K	﹤0.01%	1118
2018 Q4	$292K	Sell	79,600 -25,000	-24%	-$170K	﹤0.01%	1132
2018 Q3	$897K	Buy	104,600 +19,600	+23%	+$196K	0.01%	927
2018 Q2	$933K	Hold	85,000	–	–	0.01%	898
2018 Q1	$980K	Hold	85,000	–	–	0.01%	849
2017 Q4	$881K	Hold	85,000	–	–	0.01%	886
2017 Q3	$1.35M	Buy	+85,000	New	+$1.18M	0.02%	734

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bridgeway Capital Management's CRVS Position: Q1 2026 in Review

Bridgeway Capital Management held its Corvus Pharmaceuticals (CRVS) position steady in Q1 2026 at 26,700 shares worth $391K. The position accounts for 0.01% of the portfolio, ranked #868.

Bridgeway Capital Management first reported a position in CRVS in Q3 2017 and has held it in 33 quarters since. The position peaked at $1.35M in Q3 2017. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

Bridgeway Capital Management held 26,700 shares of Corvus Pharmaceuticals worth $391K as of Q1 2026.
Bridgeway Capital Management left its Corvus Pharmaceuticals share count unchanged in Q1 2026.
Corvus Pharmaceuticals made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #868 holding.
Bridgeway Capital Management first reported a position in Corvus Pharmaceuticals in Q3 2017 and has held it in 33 quarters since.
Bridgeway Capital Management's Corvus Pharmaceuticals position peaked at $1.35M in Q3 2017.
164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.